Stock comparison
Halozyme Therapeutics
Ironwood Pharmaceuticals
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
IRWD
Ironwood Pharmaceuticals
Market cap
$645.28M
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | IRWD | Winner |
|---|---|---|---|
| Warren Buffett | 79B | 47D | HALO |
| Benjamin Graham | 83A | 25F | HALO |
| Philip Fisher | 65B | 41D | HALO |
| Peter Lynch | 53D | 26F | HALO |
| Joel Greenblatt | 40D | 69B | IRWD |
| Charlie Munger | 80C | 68D | HALO |
| Terry Smith | 84A | 66C | HALO |
Side-by-side metrics
| Metric | HALO | IRWD |
|---|---|---|
| Market cap | $8.1B | $645.28M |
| P/E (TTM) | 24.0x | 4.5x |
| EV/EBIT | 10.2x | 9.0x |
| ROIC (TTM) | 23.65% | 43.86% |
| Gross margin | 81.24% | 99.75% |
| Net margin | 23.13% | 41.76% |
| Revenue CAGR 5y | 33.23% | -8.02% |
| EPS CAGR 5y | -1.98% | -53.69% |
| Debt / Equity | 1.0x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- Revenue CAGR 5y33.23%vs -8.02%+124%
- EPS CAGR 5y-1.98%vs -53.69%+96%
- Market cap$8.1Bvs $645.28M+92%
IRWD leads on
- Debt / Equity-vs 1.0x+135%
- P/E (TTM)4.5xvs 24.0x+81%
- ROIC (TTM)43.86%vs 23.65%+46%
- Net margin41.76%vs 23.13%+45%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.